Table 1.
Low molecular weight VDAs in clinical trials
| Drug name | Company | Drug type | Developmental phase |
|---|---|---|---|
| CA-4-P (Zybrestat) | OxiGene http://www.oxigene.com/ | Tubulin binding agent | Phase I/II/III |
| CA-1-P (Oxi4503) | OxiGene http://www.oxigene.com/ | Tubulin binding agent | Phase I |
| ZD6126 | First developed by AstraZeneca http://www.astrazeneca.com/Now licensed to Angiogene http://www.angiogene.co.uk/ | Colchicine analogue | Reached Phase II |
| AVE8062 | Aventis http://www.sanofi-aventis.com/ | Combretastatin prodrug | Phase I/II |
| ABT-751 | Abbott http://www.abbott.com/ | Sulfonamide, β-tubulin inhibitor | Phase I |
| NPI-2358 | Nereus http://www.nereuspharm.com/ | Tubulin binding agent, derived from marine fungus | Phase I |
| MPC-6827 (Azixa) | Myriad Pharmaceuticals http://www.myriad.com/ | Tubulin binding agent | Phase I/II |
| CYT997 | Cytopia http://www.cytopia.com.au/ | Tubulin binding agent | Phase I/II |
| BCN105 | Bionomics http://www.bionomics.com.au/ | Tubulin binding agent | Phase I |